Aclaris Therapeutics, Inc. (ACRS)Healthcare | Biotechnology | Wayne, United States | NasdaqGS
6.01 USD
-0.15
(-2.435%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 6.01 |
Hot Take ↕ | Aug. 22, 2026, 5:33 a.m. EDT
The investment case here is defined by a stark contradiction between the company's precarious financial reality and the aggressive optimism of retail investors. Fundamentally, Aclaris is a value trap in disguise; despite a 'strong buy' analyst recommendation, the business is hemorrhaging cash with negative operating margins, shrinking revenues, and a massive 91% decline in share price over the last decade. The balance sheet offers no safety net, and the stock trades at a premium to book value despite generating no free cash flow. However, the short-term outlook is buoyed by a speculative frenzy. The options chain reveals a classic biotech setup where traders are betting on a binary event—likely a clinical trial result—rather than sustainable earnings. The heavy open interest at distant strikes ($10, $8) shows a collective belief that the stock can double or triple quickly, ignoring the fact that the company is burning through its cash reserves. While the statistical models see only noise, the options flow suggests a high-risk, high-reward gamble is currently priced in. This is not a buy-and-hold opportunity; it is a volatile swing trade dependent entirely on the next data point. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.103426 |
| MSTL | 0.136006 |
| AutoARIMA | 0.150263 |
| AutoETS | 0.150265 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 2.50 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.786 |
| Excess Kurtosis | -0.46 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.485 |
| Revenue per Share | 0.064 |
| Market Cap | 884,665,408 |
| Forward P/E | -7.40 |
| Beta | 0.78 |
| Website | https://www.aclaristx.com |
As of Aug. 22, 2026, 5:33 a.m. EDT: Speculators are positioning for significant volatility rather than a clear directional bet. Call open interest is heavily skewed toward out-of-the-money strikes ($10, $8, $7), suggesting a hope for a massive rally, while put open interest clusters deep in-the-money ($2, $3, $4), indicating a hedge against a crash to pennies. This 'straddle' style positioning implies traders expect binary event-driven moves typical of biotech, but the lack of directional bias in volume suggests uncertainty about which way the catalyst will push the price.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.0201006 |
| Address1 | 701 Lee Road |
| Address2 | Suite 103 |
| All Time High | 33.88 |
| All Time Low | 0.59 |
| Ask | 7.2 |
| Ask Size | 1 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 1,787,840 |
| Average Daily Volume3 Month | 1,893,263 |
| Average Volume | 1,893,263 |
| Average Volume10Days | 1,787,840 |
| Beta | 0.783 |
| Bid | 4.41 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 0.891 |
| City | Wayne |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.01 |
| Current Ratio | 3.462 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 6.17 |
| Day Low | 5.95 |
| Debt To Equity | 1.485 |
| Display Name | Aclaris Therapeutics |
| Earnings Call Timestamp End | 1,715,115,600 |
| Earnings Call Timestamp Start | 1,715,115,600 |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,793,881,800 |
| Earnings Timestamp Start | 1,793,881,800 |
| Ebitda | -85,525,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -9.295 |
| Enterprise To Revenue | 96.722 |
| Enterprise Value | 794,959,360 |
| Eps Current Year | -0.65111 |
| Eps Forward | -0.812 |
| Eps Trailing Twelve Months | -0.57 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.6272 |
| Fifty Day Average Change | 0.3828001 |
| Fifty Day Average Change Percent | 0.068026744 |
| Fifty Two Week Change Percent | 202.01006 |
| Fifty Two Week High | 6.6 |
| Fifty Two Week High Change | -0.5899997 |
| Fifty Two Week High Change Percent | -0.08939389 |
| Fifty Two Week Low | 1.74 |
| Fifty Two Week Low Change | 4.2700005 |
| Fifty Two Week Low Change Percent | 2.4540231 |
| Fifty Two Week Range | 1.74 - 6.6 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,444,138,200,000 |
| Float Shares | 109,898,694 |
| Forward Eps | -0.812 |
| Forward P E | -7.4014783 |
| Free Cashflow | -41,970,624 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 69 |
| Fullday Change | -0.15 |
| Fullday Change Percent | -2.43506 |
| Fullday Price | 6.01 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Gross Profits | -62,275,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02184 |
| Held Percent Institutions | 0.81385005 |
| Implied Shares Outstanding | 147,198,893 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. |
| Long Name | Aclaris Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 884,665,408 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_216879819 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -75,738,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 905,273,191 |
| Number Of Analyst Opinions | 10 |
| Open | 6.1 |
| Operating Cashflow | -62,059,000 |
| Operating Margins | -14.6949 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 484 324 7933 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 6.01 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 6.16 |
| Price Eps Current Year | -9.2303915 |
| Price Hint | 2 |
| Price To Book | 6.7452307 |
| Price To Sales Trailing12 Months | 107.63663 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.462 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.27273 |
| Region | US |
| Regular Market Change | -0.15 |
| Regular Market Change Percent | -2.43506 |
| Regular Market Day High | 6.17 |
| Regular Market Day Low | 5.95 |
| Regular Market Day Range | 5.95 - 6.17 |
| Regular Market Open | 6.1 |
| Regular Market Previous Close | 6.16 |
| Regular Market Price | 6.01 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 1,220,839 |
| Return On Assets | -0.2898 |
| Return On Equity | -0.59096 |
| Revenue Growth | -0.083 |
| Revenue Per Share | 0.064 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 147,198,893 |
| Shares Percent Shares Out | 0.0999 |
| Shares Short | 14,710,712 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 13,357,058 |
| Short Name | Aclaris Therapeutics, Inc. |
| Short Percent Of Float | 0.113400005 |
| Short Ratio | 7.49 |
| Source Interval | 15 |
| State | PA |
| Symbol | ACRS |
| Target High Price | 16.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 10.2 |
| Target Median Price | 10.0 |
| Total Cash | 91,556,000 |
| Total Cash Per Share | 0.622 |
| Total Debt | 1,850,000 |
| Total Revenue | 8,219,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.57 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.1222 |
| Two Hundred Day Average Change | 1.8878002 |
| Two Hundred Day Average Change Percent | 0.45795938 |
| Type Disp | Equity |
| Volume | 1,220,839 |
| Website | https://www.aclaristx.com |
| Zip | 19,087 |